Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 6:12 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2113–2136 of 2,908 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Chronic Hepatitis C
Interventions: BMS-791325, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 5
States / cities: Anaheim, California • Cypress, California • St Louis, Missouri + 2 more

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, DEN 2.5 mg, DEN 7.5 mg, DEN 15 mg, DEN 30 mg, DEN 45 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 36
States / cities: Long Beach, California • Pasadena, California • Denver, Colorado + 32 more

Conditions: Schizophrenia, Acute Episode
Interventions: Elpipodect, Risperidone, Placebo matching MK-8189, Placebo matching risperidone; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 224 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 28
States / cities: Little Rock, Arkansas • Rogers, Arkansas • Bellflower, California + 23 more

Conditions: Rheumatoid Arthritis
Interventions: Tirabrutinib, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 9
States / cities: Sacramento, California • Miami, Florida • Orlando, Florida + 6 more

Conditions: Chronic Obstructive Pulmonary Disease
Interventions: NVA237, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 440 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 54
States / cities: Homewood, Alabama • Jasper, Alabama • *See Various Dept.'s*, Arizona + 43 more

Conditions: Rheumatoid Arthritis
Interventions: Lovastatin, Placebo; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 70 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 15
States / cities: Birmingham, Alabama • San Francisco, California • Aurora, Colorado + 12 more

Conditions: Dyslipidaemia
Interventions: TAP311 capsules, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 279 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Miramar, Florida

Conditions: Healthy Volunteer, Opioid-use Disorder
Interventions: INDV-2000, Placebo, SUBOXONE® sublingual film; Drug
Lead sponsor: Indivior Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 3
States / cities: Baltimore, Maryland • DeSoto, Texas • San Antonio, Texas

Conditions: Migraine, With or Without Aura
Interventions: Atogepant, Placebo-matching Atogepant; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 834 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 75
States / cities: Birmingham, Alabama • Chandler, Arizona • Carlsbad, California + 66 more

Conditions: Congenital Adrenal Hyperplasia
Interventions: Crinecerfont, Placebo; Drug
Lead sponsor: Neurocrine Biosciences; Industry
Eligibility: 18 Years and older
Enrollment: 182 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 20
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 17 more

Conditions: Irritable Bowel Syndrome
Interventions: Fecal microbiota transplantation capsules, Placebo capsules; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 19 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 3
States / cities: Hamden, Connecticut • New York, New York • The Bronx, New York

Conditions: Safety in Normal Volunteers
Interventions: EDP-788, Placebo; Drug
Lead sponsor: Enanta Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Tyrosol, Creatine, Endurance Performance, Cognition, Mood
Interventions: Tyrosol, Creatine Monohydrate, Resistant Dextrin; Dietary Supplement
Lead sponsor: Applied Science & Performance Institute; Industry
Eligibility: 20 Years to 55 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Gastroparesis, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions: Placebo, 10mg TZP-102, 20mg TZP-102; Drug
Lead sponsor: Tranzyme, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 31
States / cities: Huntsville, Alabama • Tucson, Arizona • Jonesboro, Arkansas + 27 more

Conditions: Malaria, Vivax
Interventions: Tafenoquine 150 mg, Matched placebo 150mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 486 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 3
States / cities: Glendale, California • Overland Park, Kansas • Baltimore, Maryland

Conditions: Primary Insomnia
Interventions: VEC-162 20 mg, Placebo, VEC-162 50 mg; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 35
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 32 more

Conditions: Pain
Interventions: Oxycodone Naltrexone (a), Oxycodone Naltrexone (b), Placebo; Drug
Lead sponsor: Elite Laboratories, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 163 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015
U.S. locations: 5
States / cities: Phoenix, Arizona • Pasadena, Maryland • Austin, Texas + 2 more

Conditions: Gout, Moderate Renal Impairment
Interventions: Febuxostat IR, Febuxostat XR, Febuxostat placebo, Colchicine, Naproxen, Lansoprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 189 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 89
States / cities: Birmingham, Alabama • Muscle Shoals, Alabama • Phoenix, Arizona + 75 more

Conditions: Autistic Disorder
Interventions: D-cycloserine, Placebo; Drug
Lead sponsor: Indiana University; Other
Eligibility: 3 Years to 12 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Metabolic Syndrome
Interventions: Couscous plus fiber, Grape seed extract, Bean Soup; Other · Dietary Supplement
Lead sponsor: University of California, Davis; Other
Eligibility: 21 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 1
States / cities: Davis, California

Conditions: Migraine, Irritable Bowel Syndrome, Headache, Migraine
Interventions: Lactobacillus plantarum (CECT7484 and CECT7485)/ Pediococcus acidilactici (CECT7483), Placebo Comparator: Placebo; Dietary Supplement · Other
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Alcoholism, Alcohol Use Disorder (AUD)
Interventions: Topiramate, Medical Management, Inactive Placebo; Drug · Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 70 Years
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania

Conditions: Lymphoma
Interventions: Ibrutinib, Placebo, Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (or equivalent); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 838 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 44
States / cities: Tucson, Arizona • Greenbrae, California • La Jolla, California + 41 more

Conditions: Chronic Pain, Opioid Dependence
Interventions: Varenicline, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Rochester, Minnesota

Search by objective public record fields.

A Single Ascending Dose Study of BMS-791325 in HCV Infected Subjects

A New Oral Treatment For Type II Diabetes Mellitus

An Active-Controlled Early Phase Study of Elpipodect (MK-8189) in Adults With Schizophrenia (MK-8189-005)

Study to Evaluate Safety and Pharmacokinetics of GS-4059 (Tirabrutinib) in Healthy Volunteers and Participants With Rheumatoid Arthritis (RA)

NVA237 Versus Placebo 12-week Efficacy Study

Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis

Safety and Pharmacokinetis of TAP311 in Dyslipidemic Patients

Study to Assess Repeated Doses of INDV-2000 in Healthy Volunteers and in Treatment Seeking Individuals With Opioid Use Disorder

Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention

Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia

Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome

Evaluation of the Safety and Pharmacokinetics of a Single Oral Dose of EDP-788

The Effects of Tyrosol and Creatine on Exercise Performance and Cognition in Healthy Adults

Affects of Once-daily Oral Administration of TZP-102 on the Treatment of Symptoms Associated With Diabetic Gastroparesis

Assessment of Any Potential Retinal Effects of Tafenoquine (TQ)

VEC-162 Study in Adult Patients With Primary Insomnia

A Study to Evaluate Safety and Efficacy Following Dosing of Oxycodone/Naltrexone for Treatment of Adults With Pain Following Bunionectomy Surgery

Efficacy and Safety of Extended Release and Immediate Release Febuxostat in Participants With Gout and Moderate Renal Impairment

Safety and Effectiveness of D-Cycloserine in Children With Autism

The Effect of Whole Beans on Inflammation and Satiety

Effects of a Multispecies Probiotic on Migraine

A Randomized, Double-blind Placebo-Controlled Pharmacogenetic Study of Topiramate in European-American Heavy Drinkers

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Pilot Study of Varenicline to Treat Opioid Dependence